Industry Revenues:

• Human Nutrition & Health: approx. 40%
• Animal Nutrition & Health: approx. 30%
• Specialty Products: approx. 20%
• Industrial Products: approx. 10%

TOP 3 Markets:

• USA: approx. 50%
• Europe: approx. 25%
• Asia: approx. 15%

Balchem Corporation mainly generates its revenues from the Human Nutrition & Health and Animal Nutrition & Health sectors. These two segments together account for about 70% of total revenues. Specialty Products and Industrial Products also contribute significantly to revenue, but to a lesser extent.

Geographically, the US market is the largest revenue contributor, followed by Europe and Asia. Together, these markets cover the majority of global revenues, with a focus on the USA, highlighting the strong market presence and strategic importance of the region.

Production Sites: USA, Canada, Italy

Balchem Corporation mainly produces its products in several production facilities in the USA. In addition, the company also has production capacities in Canada and Italy. This geographical distribution enables Balchem to efficiently respond to demand in different markets and to take advantage of logistical benefits.

Revenue Growth: Estimated at 8-10% annually (2025 based on historical data and industry trends)

Profit Growth: Estimated at 7-9% annually (2025 based on historical data and industry trends)

Balchem Corporation pursues a strategy based on diversification and innovation. The company focuses on expanding its product portfolio in the areas of specialty chemicals, nutrition and health solutions, and animal nutrition.

A key component of the growth strategy is the continuous investment in research and development to develop innovative products that meet changing customer requirements. Additionally, Balchem aims for strategic acquisitions to strengthen its market presence and integrate new technologies.

Furthermore, the company emphasizes tapping into new markets and expanding its global reach, especially in emerging markets, to benefit from the increasing demand for high-quality nutrition and health solutions.

Main raw materials: Choline, minerals, vitamins
Main supplying countries: USA, China, Germany

Balchem Corporation imports a variety of raw materials necessary for the production of their products. The key raw materials include choline, minerals, and vitamins used in various nutritional and health products.

The USA is a significant supplier, especially for choline and certain minerals. China is an important supplier of vitamins and other chemical components required in production. Germany also supplies high-quality raw materials, particularly in the specialty chemicals sector.

Diversifying supply chains across multiple countries helps Balchem minimize risks and ensure a stable supply.

Market Share: Estimated 5-10% in the specialty chemicals industry (2025) Research & Development: Investments of approximately 4% of revenue (2024) Gross Margin: 33% (2024)

Balchem Corporation possesses a solid competitive advantage that is composed of several factors. The company has established itself in the specialty chemicals industry and holds an estimated market share of 5-10%. This enables Balchem to have a certain pricing power and market presence.

A key component of their competitive advantage is the continuous investment in research and development, which accounts for about 4% of revenue. This demonstrates Balchem's commitment to developing innovative products and differentiating itself from the competition.

The 33% gross margin underscores the efficiency and the company's ability to control costs while offering high-quality products. These metrics indicate that Balchem Corporation is well positioned to succeed in a competitive market environment.

Institutional Investor Share: approximately 87% (2025, estimated)

Insider Purchases/Sales: No significant transactions in the last quarter (2025, estimated)

The institutional investor share in Balchem Corporation is approximately 87%, indicating a high level of trust from institutional investors in the company. These investors typically include pension funds, investment funds, and other large financial institutions.

There were no significant insider purchases or sales in the last quarter, suggesting that the management and other insiders do not currently anticipate any significant changes in the company's valuation. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Balchem Corporation: Estimate: 5-7% (2025)

Top competitors and their market shares:

1. DSM-Firmenich: 15%
2. BASF SE: 12%
3. Cargill, Incorporated: 10%
4. Archer Daniels Midland Company (ADM): 9%
5. Kerry Group: 8%
6. Balchem Corporation: 5-7%
7. Givaudan: 5%
8. IFF (International Flavors & Fragrances): 4%
9. Symrise AG: 3%
10. Tate & Lyle: 2%

Economic moat of Balchem Corporation:

Balchem Corporation has a moderate economic moat, mainly stemming from its specialization in niche markets such as human nutrition, animal nutrition, and specialty chemicals. The company benefits from its innovation capabilities and the ability to offer specialized solutions tailored to its customers' needs.

Compared to larger competitors like DSM-Firmenich or BASF, which have extensive research and development resources and a broad product portfolio, Balchem's economic moat is less pronounced. These larger companies often have a stronger global presence and can leverage economies of scale more effectively.

However, Balchem's focus on specialized markets allows it to differentiate itself from general industry trends and efficiently meet specific customer needs. This can provide an advantage in certain segments, but overall, the economic moat is considered moderate compared to industry leaders.

Revenue Growth: 7.8% (2024) Profit Growth: 6.5% (2024) EBITDA Margin: 22% (2024)

Balchem Corporation achieved solid revenue growth of 7.8% in 2024, driven by strong demand in the human nutrition and animal nutrition sectors. The 6.5% increase in profits indicates that the company is able to effectively manage its costs and enhance its profitability.

The EBITDA margin of 22% suggests healthy operational efficiency, which is attractive to investors as it signals good cost control and a strong market position.

Additionally, Balchem has invested in research and development in recent years to develop innovative products that could support future growth. These strategic investments could position the company advantageously for long-term growth.

Overall, Balchem Corporation appears to be a promising investment due to its stable financial performance and strategic direction. However, investors should also consider external factors such as market conditions and regulatory changes.

Dividend yield: 0.5% (2024)
Dividend growth: 5% (average over the last 5 years)

Balchem Corporation pays a dividend that has been steadily growing in recent years. The dividend yield is approximately 0.5%, which is relatively low compared to other companies in the industry.

The reliability of dividend payments is high as Balchem has a solid financial foundation and a consistent dividend policy. The company has been regularly paying dividends in recent years and has also consistently increased them, indicating a stable earnings situation and a sustainable business model.